Biologists face criticism from tech friends about the slow progress in medical advancements, blaming long feedback loops in biology. Clinical trials, the final validation step for therapeutics, are costly and bureaucratic, hindering progress. Opinions on regulatory concerns vary, with a focus on the difficulty of conducting trials. Suggestions for policy changes include increasing participant compensation and encouraging new trial designs. Companies are often hesitant to adopt more efficient practices due to fear of regulatory risk. A vibe shift towards medical innovation is needed, along with increased transparency in clinical trial costs and FDA guidance. Overall, a combination of policy, culture, and technological disruption is necessary for progress.
https://www.writingruxandrabio.com/p/on-clinical-trial-abundance